Company / Cash & Equivalents
Avidity Biosciences, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$382.5M
FY2025
5-year range
$185.1M / $382.5M
FY2021-FY2025
Trend
+74.0%
vs FY2024
Sector context
#51 of 207
Health Care
What the data says
Avidity Biosciences, Inc.'s cash & equivalents of $383M is higher than 75% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 7 years, ranging from $95M in FY2019 to $383M in FY2025.
Based on SEC 10-K filings.
$383M in FY2025 with a 5-year CAGR of +3.5%. Top quartile in the Health Care sector.
Improved from $185M to $383M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +4.0%
- 5-Year CAGR
- +3.5%
- 10-Year CAGR
- -
Sector benchmark
-42.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.5%, indicating consistent growth.
- In FY2025, cash & equivalents increased 74.0% year-over-year.
- Ranks #51 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $382.5M | +74.0% |
| FY2024 | $219.9M | +18.8% |
| FY2023 | $185.1M | -45.6% |
| FY2022 | $340.4M | +6.2% |
| FY2021 | $320.4M | -0.3% |
| FY2020 | $321.5M | +239.9% |
| FY2019 | $94.6M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026